Natera Q3 2026: Revenue +34% but Gross Margin Slips; Operating Leverage Still Unproven

What happened

Natera reported Q3 2026 revenue of $794.0 million, up 34.1% year-over-year, surpassing the 30% growth threshold that would have increased conviction. However, gross margin dipped to 64.7% from 64.9% a year ago, remaining within the guided 64–66% band but showing no improvement. The press release excerpt does not include operating expense or loss figures, leaving the critical operating leverage question unanswered. This continues the pattern of strong top-line momentum that has yet to translate into visibly narrowing losses, as highlighted in the prior master report. Investors should remain cautious given high valuation and increasing competitive pressure from Labcorp and Foundation Medicine.

Implication

The 34% revenue growth is encouraging and indicates continued demand for Signatera and other tests. However, the slight gross margin decline suggests pricing or mix pressure, and the absence of opex data prevents confirmation that losses are narrowing. Management has guided to 'net cash inflow positive' for 2026, but the first quarter showed an operating loss of $(93.5)M, and the company needs to demonstrate that Q2 and Q3 improved. Until quarterly reports show expense growth lagging revenue growth and operating losses declining, the valuation at ~31B market cap remains demanding. Investors should watch for the next 10-Q to assess operating leverage and any update on Japan PMDA approval, which was expected in Q2 2026.

Thesis delta

The thesis is unchanged: revenue growth remains robust, but the key watchpoint is operating leverage. Q3 revenue of $794M (+34% YoY) meets the growth hurdle, but gross margin slightly declined and opex data is missing. No evidence yet that losses are narrowing, so the WAIT rating stands. Confidence in the thesis is moderate pending full financial disclosure.